Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA […]